3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Se Hoon Choi†, Young Hye Kim†, Luisa Quinti, Rudolph E. TanziEmail author and Doo Yeon Kim
Received: 20 October 2016Accepted: 3 December 2016Published: 9 December 2016
Abstract
Alzheimer’s disease (AD) transgenic mice have been used as a standard AD model for basic mechanistic studies and drug discovery. These mouse models showed symbolic AD pathologies including β-amyloid (Aβ) plaques, gliosis and memory deficits but failed to fully recapitulate AD pathogenic cascades including robust phospho tau (p-tau) accumulation, clear neurofibrillary tangles (NFTs) and neurodegeneration, solely driven by familial AD (FAD) mutation(s). Recent advances in human stem cell and three-dimensional (3D) culture technologies made it possible to generate novel 3D neural cell culture models that recapitulate AD pathologies including robust Aβ deposition and Aβ-driven NFT-like tau pathology. These new 3D human cell culture models of AD hold a promise for a novel platform that can be used for mechanism studies in human brain-like environment and high-throughput drug screening (HTS). In this review, we will summarize the current progress in recapitulating AD pathogenic cascades in human neural cell culture models using AD patient-derived induced pluripotent stem cells (iPSCs) or genetically modified human stem cell lines. We will also explain how new 3D culture technologies were applied to accelerate Aβ and p-tau pathologies in human neural cell cultures, as compared the standard two-dimensional (2D) culture conditions. Finally, we will discuss a potential impact of the human 3D human neural cell culture models on the AD drug-development process. These revolutionary 3D culture models of AD will contribute to accelerate the discovery of novel AD drugs.
https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-016-0139-7
- Forums
- ASX - By Stock
- ATH
- New Tanzi paper
New Tanzi paper
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $4.125K | 824.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
58 | 64293651 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 29230739 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1500000 | 0.005 |
56 | 63055651 | 0.004 |
47 | 46138652 | 0.003 |
18 | 39784402 | 0.002 |
13 | 92470101 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 500000 | 1 |
0.005 | 39008483 | 22 |
0.006 | 34263249 | 13 |
0.007 | 22226649 | 17 |
0.008 | 14399594 | 14 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
ATH (ASX) Chart |